Kairos Pharma Ltd. (NYSE American: KAPA) provided a mid-year 2026 update highlighting plans to expand its oncology pipeline through the proposed acquisition of worldwide rights to CL-741, a Phase 1-ready oral c-MET kinase inhibitor from Celyn Therapeutics targeting EGFR-mutated lung cancer and other cancers. The company said CL-741 would complement its existing portfolio, which includes ENV-105, KROS-201, KROS-102 and ENV-205.
Looking ahead, Kairos expects to initiate a Phase 1 study of CL-741, advance ongoing clinical trials of ENV-105 in prostate cancer and non-small cell lung cancer, present data at scientific meetings and pursue pharmaceutical collaborations. The company also noted it has secured more than $8 million in non-dilutive funding to support development of its preclinical and clinical programs.
To view the full press release, visit https://ibn.fm/WuBOf.
Based in Los Angeles, California, Kairos Pharma Ltd. (NYSE American: KAPA) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Kairos Pharma’s lead candidate, ENV-105, is an antibody that targets CD105—a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer aimed at addressing significant unmet medical needs. As of the date of this press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator.
NOTE TO INVESTORS: The latest news and updates relating to KAPA are available in the company’s newsroom at https://ibn.fm/KAPA.
